



Dynavax Technologies Corporation
Investor Relations Department
2929 Seventh Street
Berkeley, CA 94710
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: DVAX

Last Trade:	17.73
Trade Time:	9:44 AM ET Feb 21, 2018
Change:	0.48 (+2.788%)
Day Range	17.36 - 18.05
52-Week Range	3.90 - 24.45
Volume	273,741

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Dynavax is a clinical-stage immunology company focused on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Dynavax is developing product candidates for use in m... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Feb 21, 2018
[Dynavax's HEPLISAV-B™ \[Hepatitis B Vaccine \(Recombinant\), Adjuvanted\] Recommended by CDC Advisory Committee on Immunization Practices for the Prevention of Hepatitis B in Adults](#)

Feb 20, 2018
[Dynavax Secures \\$175 Million in Non-Dilutive Debt Financing](#)

Feb 14, 2018
[Dynavax to Present at the RBC Capital Markets Global Healthcare Conference](#)

Feb 2, 2018
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Jan 12, 2018
[Dynavax Technologies Corporation Announces Inducement Grants under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Upcoming Events [\[View all \]](#)

Feb 21, 2018 1:35 PM ET
[RBC Capital Markets Global Healthcare Conference](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 13, 2017
[Annual Report \(10-K\)](#)

Jul 10, 2017
[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017
[Quarterly Report \(10-Q\)](#)

Aug 7, 2017
[Quarterly Report \(10-Q\)](#)

May 8, 2017
[Quarterly Report \(10-Q\)](#)